Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Boston Scientific Corp. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Short-term (Operating) Activity Ratios
- Price to FCFE (P/FCFE)
- Operating Profit Margin since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Boston Scientific Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Boston Scientific Corp., profitability ratios (quarterly data)
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
- Gross Profit Margin
- The gross profit margin exhibited relative stability from March 2018 through March 2023. Starting near 71.37% in early 2018, it experienced a gradual decline over the period, reaching a low of approximately 64.9% in the first half of 2021. Subsequently, there was a moderate recovery, with the margin returning to just above 69% by the first quarter of 2023, indicating some improvement in production efficiency or pricing power after a dip.
- Operating Profit Margin
- The operating profit margin showed notable volatility. From around 15.33% in early 2018, it slightly increased to approximately 16.5% in mid-2018, then declined steadily through 2019 and 2020, falling to below 1% by the end of 2020, signaling substantial operating challenges. Afterwards, from 2021 onward, there was a consistent recovery, climbing back to about 13.3% by March 2023. This pattern suggests operational headwinds during 2019-2020 followed by successful management action to restore profitability.
- Net Profit Margin
- The net profit margin fluctuated considerably throughout the observed period. It peaked sharply at 43.78% in March 2020, a figure that stands out significantly and may reflect exceptional items or accounting effects. Before and after this spike, margins were generally lower, declining to negative territory near the end of 2020. From 2021 onward, margins improved modestly, stabilizing between 5% and 11%, indicating a return to more normalized earnings levels.
- Return on Equity (ROE)
- The ROE followed a trend similar to the net profit margin, with early values in 2018 around 19%, dropping during 2019 and 2020, and reaching a negative figure at the end of 2020. It then showed a gradual recovery, rising to around 7% by late 2021. However, since then, ROE decreased slightly and fluctuated between 3.7% to 5% up to early 2023, indicating modest shareholder returns relative to equity invested during this timeframe.
- Return on Assets (ROA)
- The ROA mirrored the trends observed in ROE, with a peak of approximately 7.96% in early 2018 and a decline through 2019 and 2020, including a brief negative return at the end of 2020. There was a modest recovery beginning in 2021, with values generally ranging between 2% to 3.6% thereafter. This indicates a reduced efficiency in asset utilization compared to earlier years but some stabilization and slight improvement in more recent quarters.
Return on Sales
Return on Investment
Gross Profit Margin
Boston Scientific Corp., gross profit margin calculation (quarterly data)
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| Gross profit margin1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q1 2023 Calculation
Gross profit margin = 100
× (Gross profitQ1 2023
+ Gross profitQ4 2022
+ Gross profitQ3 2022
+ Gross profitQ2 2022)
÷ (Net salesQ1 2023
+ Net salesQ4 2022
+ Net salesQ3 2022
+ Net salesQ2 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Gross Profit Trends
- Over the analyzed quarters, gross profit demonstrates a generally positive trajectory with some fluctuations. Starting at $1,707 million in March 2018, gross profit exhibits growth, reaching $2,054 million by December 2019. A notable dip occurs in mid-2020, particularly in June when gross profit falls sharply to $1,212 million, likely reflecting adverse conditions in that period. Subsequently, gross profit recovers steadily throughout the remainder of 2020 and into 2021, peaking at $2,155 million by December 2021. From early 2022 onward, gross profit maintains levels above $2,000 million, rising to $2,349 million by March 2023, indicating resilience and overall growth over the medium term.
- Net Sales Patterns
- Net sales mirror some patterns seen in gross profit, starting at $2,379 million in March 2018 and increasing gradually to $2,904 million by December 2019. Sales experience a marked contraction in the first half of 2020, dropping to $2,003 million in June 2020, which aligns with the gross profit dip, suggesting external factors impacting revenue during this timeframe. Recovery is evident from September 2020 onwards, with net sales reaching a peak of $3,242 million in December 2022. By March 2023, net sales advance further to $3,389 million, highlighting sustained revenue growth and successful sales momentum.
- Gross Profit Margin Analysis
- The gross profit margin remains relatively stable throughout the period, oscillating narrowly around the high 60% range. From values exceeding 71% in early 2019, the margin shows a gradual decline starting mid-2019, reaching a low near 64.9% by mid-2021. Subsequently, it recovers and stabilizes between 68.7% and 69.0% during 2022 and early 2023. This pattern suggests that despite fluctuations in sales and gross profit, the company has maintained consistent operational efficiency and cost control, enabling it to preserve strong profitability margins.
- Overall Insights
- The data indicates that the company encountered a disruption around mid-2020, reflected in declines in both gross profit and net sales. However, the subsequent recovery and steady growth in these metrics demonstrate effective management and market resilience. The relatively stable gross profit margin throughout the periods analyzed further underscores the company's ability to manage production costs in line with revenue. The trends suggest positive underlying business fundamentals with solid revenue generation and profitability sustained over time.
Operating Profit Margin
Boston Scientific Corp., operating profit margin calculation (quarterly data)
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Operating income (loss) | ||||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| Operating profit margin1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q1 2023 Calculation
Operating profit margin = 100
× (Operating income (loss)Q1 2023
+ Operating income (loss)Q4 2022
+ Operating income (loss)Q3 2022
+ Operating income (loss)Q2 2022)
÷ (Net salesQ1 2023
+ Net salesQ4 2022
+ Net salesQ3 2022
+ Net salesQ2 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data reveals several notable trends across the analyzed periods. Net sales generally exhibit an upward trajectory, with some fluctuations. Starting at $2,379 million in March 2018, net sales increased to $3,389 million by March 2023. The periods within 2020 show a dip, notably in the second quarter with $2,003 million, likely reflecting external challenges. However, a recovery is apparent in subsequent quarters, with sales surpassing previous highs by the end of the observation period.
Operating income demonstrates more volatility over the same timeframe. Initial values were relatively strong in 2018, peaking at $541 million in March 2019, but a significant decline occurs in 2020 with negative values recorded in the second and third quarters (-$71 million and -$205 million, respectively). Following this downturn, operating income recovers to positive figures and continues to grow, reaching $552 million by March 2023, which is the highest quarterly figure within the dataset.
The operating profit margin percentage data, though sparse in earlier periods, corresponds with the trends in operating income and net sales. Margins were consistently robust prior to 2020, peaking around 16.5% in June 2019. The margins contracted sharply during 2020, falling close to or below zero, correlating with the operating income losses in that year. Subsequently, profitability improved steadily, with margins increasing to over 13% by the first quarter of 2023.
- Net Sales
- Overall growth from $2,379 million to $3,389 million over five years.
- Significant dip during 2020 second quarter to $2,003 million, followed by recovery.
- Strong sales performance in 2021 through first quarter 2023.
- Operating Income (Loss)
- Strong performance in 2018 and early 2019, peaking at $541 million.
- Notable decline in 2020 with two quarters reporting negative operating income.
- Gradual recovery post-2020, reaching a new high of $552 million by March 2023.
- Operating Profit Margin
- Healthy margins (around 15-16%) before 2020.
- Sharp contraction to near zero or negative margin during 2020.
- Consistent margin recovery beginning in late 2020, surpassing 13% by early 2023.
In conclusion, the company experienced a significant impact on profitability during 2020, likely due to extraordinary circumstances affecting operating income and profit margins despite a brief, sharp decline in net sales. The post-2020 period marks a strong recovery and growth phase with improving profitability and increasing sales, suggesting successful operational adjustments and market conditions that favor financial performance.
Net Profit Margin
Boston Scientific Corp., net profit margin calculation (quarterly data)
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Net income (loss) | ||||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| Net profit margin1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q1 2023 Calculation
Net profit margin = 100
× (Net income (loss)Q1 2023
+ Net income (loss)Q4 2022
+ Net income (loss)Q3 2022
+ Net income (loss)Q2 2022)
÷ (Net salesQ1 2023
+ Net salesQ4 2022
+ Net salesQ3 2022
+ Net salesQ2 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The net income exhibited significant volatility over the examined quarterly periods. During 2018 and early 2019, net income showed moderate fluctuations, ranging approximately between 126 million and 555 million US dollars. A notable spike occurred in the last quarter of 2019, when net income surged sharply to 3,996 million US dollars, an exceptional outlier compared to other periods. Following this spike, the net income figures declined sharply in 2020, even turning negative in two consecutive quarters (second and third quarters), indicating periods of loss. Recovery became evident starting in the last quarter of 2020, with positive net income values reestablished and generally rising through 2021. The net income continued to fluctuate into 2022 and early 2023, but values were more stable and positive compared to the immediate early 2020 period.
Net sales displayed a generally upward trend across the entire period. Beginning slightly below 2,400 million US dollars in early 2018, net sales showed steady increases through 2019, peaking near 2,900 million US dollars in the final quarter of that year. The first half of 2020 saw a noticeable decline, dropping to around 2,000 million US dollars, likely impacted by external challenges during that time. However, sales rebounded strongly in the second half of 2020 and continued to increase steadily into 2021 and 2022. Recent quarters, including the first quarter of 2023, saw net sales reach new highs near 3,400 million US dollars, reflecting consistent growth momentum.
The net profit margin percentage demonstrated variability aligned with the fluctuations in net income relative to net sales. Early data points in 2018 are incomplete, but starting from early 2019, margins exhibited moderate levels ranging roughly from 10% to 18%. The extraordinary increase in net income during the last quarter of 2019 resulted in an exceptionally high profit margin surpassing 40%, indicative of an uncommon event or gain during that period. Subsequently, the profit margin contracted sharply in early 2020, even becoming negative during the quarters with losses, suggesting periods of reduced profitability or operational challenges. Recovery trends in profit margins were apparent through late 2020 and into 2021, with margins returning to the single-digit to low double-digit percentages. The profit margins have remained relatively stable but modest through 2022 and early 2023, generally fluctuating between around 5% and 7%, which may indicate normalization of profitability following earlier disruptions.
Overall, the financial data indicate that while net sales have maintained a generally positive growth trajectory over the multi-year period, net income and profit margins experienced marked volatility, especially around 2019 and 2020. The extraordinary net income surge at the end of 2019 stands out as a significant anomaly, followed by challenging profitability in 2020 likely influenced by external and operational factors. Subsequent quarters show resilience and recovery, with improving profitability and continued sales growth into early 2023.
Return on Equity (ROE)
Boston Scientific Corp., ROE calculation (quarterly data)
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Net income (loss) | ||||||||||||||||||||||||||||
| Stockholders’ equity | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| ROE1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q1 2023 Calculation
ROE = 100
× (Net income (loss)Q1 2023
+ Net income (loss)Q4 2022
+ Net income (loss)Q3 2022
+ Net income (loss)Q2 2022)
÷ Stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable patterns and trends in net income, stockholders’ equity, and return on equity (ROE).
- Net Income (Loss)
- Net income demonstrated significant volatility across the observed periods. It peaked sharply in the quarter ending December 31, 2019, reaching a notably high value of 3,996 million USD, which represents an outlier compared to other quarters. In the quarters following this peak, net income plunged into negative territory during the first three quarters of 2020, indicating losses of substantial magnitude (-147 million USD to -155 million USD). Subsequently, net income recovered and stabilized with mostly positive results, though the magnitude was more moderate, generally ranging between approximately 95 million and 419 million USD. The latest reported quarter, March 31, 2023, also shows an increase in net income to 314 million USD, reflecting a positive trend after a period of fluctuations.
- Stockholders’ Equity
- Stockholders’ equity exhibited a consistent upward trend throughout the entire period. Starting at 7,030 million USD in March 2018, equity grew steadily, reaching around 17,850 million USD by the first quarter of 2023. This increment suggests persistent reinvestment of earnings and/or capital injections, contributing to a strengthened capital base. Despite some minor fluctuations, the overall trajectory is one of growth, which reflects positively on the company’s financial stability and capacity to support operations and growth initiatives.
- Return on Equity (ROE)
- ROE data is only available from the quarter ending December 31, 2018, onward. Initially, ROE showed relatively strong performance, ranging from approximately 11.24% to 33.87% during 2019 and early 2020. However, the subsequent impact of losses in early 2020 is evident, with ROE plunging to negative or near-zero figures (-0.54% to 1.58%) during that period. After this decline, ROE gradually improved but remained modest, typically fluctuating between 3.7% and 7.02% through 2022 and into early 2023. The stabilization at these lower levels indicates that while profitability relative to equity has recovered, it remains significantly below earlier peak values.
Overall, the company experienced a period of exceptional net income in late 2019, followed by a pronounced decline and losses coinciding with the early 2020 period, likely related to broader economic challenges. Equity growth was steady and uninterrupted, underlining strong capital accumulation despite earnings variability. Profitability per equity holders, as reflected by ROE, experienced a material decline during the downturn but showed signs of gradual recovery, albeit at a lower sustainable level relative to prior peaks.
Return on Assets (ROA)
Boston Scientific Corp., ROA calculation (quarterly data)
| Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Net income (loss) | ||||||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| ROA1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
1 Q1 2023 Calculation
ROA = 100
× (Net income (loss)Q1 2023
+ Net income (loss)Q4 2022
+ Net income (loss)Q3 2022
+ Net income (loss)Q2 2022)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net income (loss)
- The net income exhibits significant fluctuations over the observed periods. Initially, there is a strong performance in 2018 with quarterly net income values ranging from 298 million to 555 million US dollars. However, a notable drop occurs in 2019, with a steep decrease to 154 million and 126 million in the middle quarters, before a remarkable spike to 3,996 million US dollars in the final quarter of 2019. This spike appears to be an anomaly compared to the other quarters.
- Following this, the net income returns to much lower levels, with some quarters in 2020 even showing negative values (-147 million, -155 million). From 2021 onward, the net income recovers moderately, fluctuating between 95 million and 419 million US dollars, but it does not regain the unusually high level seen at the end of 2019. In early 2023, the figure measures 314 million, indicating some recovery but still within a relatively moderate range.
- Total assets
- Total assets show a consistent upward trend throughout the time frame. Starting from 19,202 million US dollars in early 2018, assets increase steadily each quarter, reaching 32,892 million by the first quarter of 2023. This indicates sustained growth in the asset base over the nearly five-year horizon without any significant interruptions or declines.
- Return on Assets (ROA)
- ROA data begins in March 2019. It shows a downward trend during 2019, dropping from 7.96% to 4.07%. At the end of 2019 and into 2020, ROA increases substantially, peaking at 15.38% in the last quarter of 2019, which correlates with the large net income spike during the same period.
- Following this peak, ROA gradually declines through 2020 and fluctuates at lower levels in 2021 and 2022, ranging between -0.27% and 3.62%, suggesting reduced profitability relative to assets during these years. In the first quarter of 2023, ROA rises slightly to 2.74%, indicating modest improvement in asset profitability.
- Overall summary
- The company experienced material volatility in net income, with a notable one-time spike at the end of 2019 that heavily influenced profitability metrics such as ROA. Despite this, the total asset base grew steadily, supporting long-term stability and potential capacity expansion. The return on assets reflects these income swings, showing peaks and troughs corresponding to the net income pattern but settling into moderate positive territory most recently. This suggests a phase of recovery or stabilization after periods of considerable income variability.